Regenity Biosciences

Regenity Biosciences is a private, commercial-stage medical technology company focused on regenerative medicine and cell therapy. It has successfully commercialized its first product, RejuvaKnee™, and maintains a robust CDM services business built on expertise in collagen, bioceramics, and synthetic polymers. The company is backed by private equity investors Cinven and Linden Capital Partners and has a global commercial footprint with regulatory approvals in 86 countries. Its strategy combines proprietary product development with a high-value services model for other medtech innovators.

Integrated platforms for bioresorbable and biocompatible materials, including collagen, bioceramics, and synthetic polymers (e.g., polyurethane), used to create scaffolds and implants that guide tissue regeneration and then safely resorb.

In meniscal repair, Regenity competes with other implant makers and allograft providers. In the CDMO space, it competes with other specialized contract manufacturers in the regenerative medicine field. Its deep, vertically integrated materials science expertise across multiple platforms is a key differentiator against more narrowly focused competitors.